Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use.

NCT01500850 is registered in ClinicalTrials.gov with ikfe-CRO GmbH as lead sponsor.

NCT NCT01500850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01500850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use.
Lead sponsor
ikfe-CRO GmbH
Phase
Phase 4
Overall status
Unknown status
Start date
October 31, 2011
Completion date
October 31, 2012
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

insulin-requiring type 2 diabetes mellitus